Morgan Stanley Genfit S.A. Transaction History

Morgan Stanley

$1.23 Trillion
Q1 2024

A detailed history of Morgan Stanley transactions in Genfit S.A. stock. As of the latest transaction made, Morgan Stanley holds 28,464 shares of GNFT stock, worth $113,002. This represents 0.0% of its overall portfolio holdings.

Number of Shares

28,464

Previous 30,763 7.47%

Holding current value

$113,002

Previous $118,000 14.41%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$3.34 - $4.04 $7,678 - $9,287	-2,299 Reduced 7.47%	28,464 $101,000
Q4 2023 Feb 13, 2024	SELL	$2.97 - $3.94 $10,694 - $14,187	-3,601 Reduced 10.48%	30,763 $118,000
Q3 2023 Nov 15, 2023	SELL	$3.15 - $4.12 $16,695 - $21,836	-5,300 Reduced 13.36%	34,364 $112,000
Q2 2023 Aug 14, 2023	SELL	$3.54 - $4.68 $12,613 - $16,674	-3,563 Reduced 8.24%	39,664 $140,000
Q1 2023 May 15, 2023	SELL	$3.93 - $4.69 $19,932 - $23,787	-5,072 Reduced 10.5%	43,227 $177,000

Q4 2022 Feb 14, 2023	SELL	$3.53 - $4.39 $30,449 - $37,868	-8,626 Reduced 15.15%	48,299 $212,000
Q3 2022 Nov 14, 2022	BUY	$3.26 - $4.86 $16,828 - $25,087	5,162 Added 9.97%	56,925 $208,000
Q2 2022 Oct 27, 2022	SELL	$3.09 - $4.25 $74,672 - $102,705	-24,166 Reduced 31.83%	51,763 $166,000
Q2 2022 Aug 15, 2022	SELL	$3.09 - $4.25 $74,672 - $102,705	-24,166 Reduced 31.83%	51,763 $166,000
Q1 2022 Oct 27, 2022	BUY	$3.14 - $5.04 $75,881 - $121,796	24,166 Added 46.69%	75,929 $304,000
Q1 2022 May 13, 2022	SELL	$3.14 - $5.04 $10,362 - $16,632	-3,300 Reduced 4.17%	75,929 $304,000
Q4 2021 Feb 14, 2022	BUY	$3.01 - $5.65 $74,927 - $140,645	24,893 Added 45.81%	79,229 $396,000
Q3 2021 Nov 15, 2021	BUY	$3.58 - $4.14 $194,522 - $224,951	54,336 New	54,336 $201,000

Others Institutions Holding GNFT

# of Institutions

Shares Held

76.8K

Call Options Held

Put Options Held

View Full List

About Genfit S.A.

Ticker GNFT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,815,500
Market Cap $198M
Description
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...

More about GNFT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account